Journal
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
Volume 68, Issue 12, Pages 871-885Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1369/0022155420937098
Keywords
biomarkers; dendritic cells; extracellular matrix; glycosaminoglycan; immunotherapy; macrophages; matrikines; myeloid cells; proteoglycan; versican; versikine
Categories
Funding
- National Institutes of Health/National Cancer Institute [R01CA252937]
- American Cancer Society [RSG-15045-01-LIB]
- Leukemia and Lymphoma Society [655118]
- Robert J. Shillman Foundation
Ask authors/readers for more resources
Versican is an extracellular matrix proteoglycan with key roles in multiple facets of cancer development, ranging from proliferative signaling, evasion of growth-suppressor pathways, regulation of cell death, promotion of neoangiogenesis, and tissue invasion and metastasis. Multiple lines of evidence implicate versican and its bioactive proteolytic fragments (matrikines) in the regulation of cancer inflammation and antitumor immune responses. The understanding of the dynamics of versican deposition/accumulation and its proteolytic turnover holds potential for the development of novel immune biomarkers as well as approaches to reset the immune thermostat of tumors, thus promoting efficacy of modern immunotherapies. This article summarizes work from several laboratories, including ours, on the role of this central matrix proteoglycan in tumor progression as well as tumor-immune cell cross-talk:
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available